The Key to Defeating COVID-19 Already Exists. We Need to Start Using It.

Dr. Harvey Risch Yale epidemiologist .

Translate this page into your preferred language Google.translate.com

Table of Contents

    EVMS COVID-19 Management Protocol

    December 27th, 2020 – An overview of the MATH+ and I-MASK+ Protocols

    Developed and Updated by Paul Marik, MD, FCP (SA), FRCP (C), FCCP, FCCM. Professor of Medicine, Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School

    This is our recommended approach to COVID-19 based on the best (and most recent) literature. This is a highly dynamic topic; therefore, we will be updating the guideline as new information emerges.


    Front Line COVID-19 Critical Care Alliance

    Prophylaxis & Treatment Protocols for COVID-19 https://covid19criticalcare.com

    Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 – updated Jan 12, 2021

    Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19


    Swiss Medic – On the Treatment of Covid-19

    Effectiveness of ivermectin against covid-19 (IVMMETA)

    Updated: March 2021
    Based on the available scientific evidence and current clinical experience, the SPR Collaboration recommends that physicians and authorities consider the following covid-19 treatment protocol for the prophylactic and early treatment of people at high risk or high exposure.

    Numerous international studies have shown that prophylactic and early treatment can significantly reduce the risk of severe or fatal covid-19 (see scientific references below).

    Website Treatment protocol

    Steven Hatfill -An Effective COVID Treatment the Media Continues to Besmirch

    Steven Jay Hatfill is an American physician, pathologist and biological weapons expert. A former biodefense researcher for the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick.

    On Friday, July 31, in a column ostensibly dealing with health care “misinformation,” Washington Post media critic Margaret Sullivan opened by lambasting “fringe doctors spouting dangerous falsehoods about hydroxychloroquine as a COVID-19 wonder cure.”

    Actually, it was Sullivan who was spouting dangerous falsehoods about this drug, something the Washington Post and much of the rest of the media have been doing for months. On May 15, the Post offered a stark warning to any Americans who may have taken hope in a possible therapy for COVID-19. In the newspaper’s telling, there was nothing unambiguous about the science — or the politics — of hydroxychloroquine: “Drug promoted by Trump as coronavirus game-changer increasingly linked to deaths,” blared the headline. Written by three Post staff writers, the story asserted that the effectiveness of hydroxychloroquine in treating COVID-19 is scant and that the drug is inherently unsafe. This claim is nonsense.

    Full Article: https://www.realclearpolitics.com/articles/2020/08/04/an_effective_covid_treatment_the_media_continues_to_besmirch_143875.html

    Reader view copy of the webpage:

    Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19

    Evidence a low dose hydroxychloroquine was the way to go. A terribly missed opportunity.

    DOI: 10.21203/rs.3.rs-107101/v1

    Conclusions: HCQ use was not associated with mortality reduction in COVID-19 patients when 5 RCTs only were evaluated, while a 9% to 33% reduced mortality was observed when observational studies were also included.
    The association was mainly apparent in studies that used lower doses of HCQ. These findings can help disentangling the debate on HCQ use in COVID-19.

    Results: A total of 27 articles were found (N=44,684 patients, including N=7,803 from 5 randomized clinical trials (RCTs)). Overall, the use of HCQ was associated with 22% lower mortality risk (pooled risk ratio: 0.78, 95%CI: 0.67 to 0.91; I2=80%, random effects). This association was found reversed when pooling only RCTs (16.7% of the overall weight; pooled risk ratio: 1.11, 0.99 to 1.24) or studies in which daily dose >400 mg or total dose >4,400 mg were used (pooled risk ratio: 1.10, 95%CI: 0.99 to 1.23 in both cases). Overall, HCQ+AZM (10 studies) was also associated with 28% lower mortality risk, but uncertainty was large (95%CI: 0.48 to 1.08; P=0.11). Use of HCQ was not associated with severe adverse events.

    Harvey A. Risch – MD, PhD , Professor of Epidemiology, Yale School of Public Health

    The Key to Defeating COVID-19 Already Exists. We Need to Start Using It.

    Physicians who have been using these medications in the face of widespread skepticism have been truly heroic. They have done what the science shows is best for their patients, often at great personal risk. I myself know of two doctors who have saved the lives of hundreds of patients with these medications, but are now fighting state medical boards to save their licenses and reputations. The cases against them are completely without scientific merit.

    Full article: https://www.newsweek.com/key-defeating-covid-19-already-exists-we-need-start-using-it-opinion-1519535 

    Reader view copy of the webpage:

    FDA obstruction: Patients die, while Trump gets the blame

    October 19, 2020

    In a recent Washington Post op-ed, seven former FDA commissioners claimed that the agency has lost credibility with the public, and they blamed it on President Trump.

    Jumping on the same bandwagon, an editorial in the once-venerable New England Journal of Medicine accused the president of “failing at every step” to stop the COVID-19 pandemic, thus enabling more than 220,000 deaths to date.

    In reality, these charges are driven by craven politics and Big Pharma conflicts of interest.
    They divert attention from the FDA’s despicable efforts to block access to effective and inexpensive generic medications. Foremost among these is hydroxychloroquine.

    It is time to clean up this mess once and for all. The FDA must remove its black-box warning, approve the emergency use authorization for outpatient HCQ use, and let doctors get on with the work of saving lives.


    Hydroxychloroquine cuts ‘virus mortality in half in high risk groups’

    06/09/2020 | 11min
    Yale University Professor Harvey Risch says all studies that examine the effectiveness of hydroxychloroquine on high risk population groups show the drug is “uniformly beneficial” in treating COVID-19.

    “What clinicians have found around the world is that a class of people called high-risk people are the ones who need to be treated,” he said. “These are people generally over aged 60 or who have chronic conditions like diabetes, or obesity, or heart disease, high blood pressure or are immuno-compromised.

    “These are people that need to be treated and the studies that look at them and them only show that hydroxychloroquine cuts the risk of hospitalisation and mortality by at least 50 per cent.”

    Mr Risch said there are no published studies that show the drug is not beneficial for those people.

    “There are plenty of other studies that show other things but the problem is they are not looking a the right people. “All of the pushback that is against this drug has been on the basis of blurring the distinction as to who needs the drugs and who needs to be treated.” https://www.skynews.com.au/details/_6188159990001

    Saved copy of the video

    Professor Harvey Risch all studies that examine the effectiveness of hydroxychloroquine on high risk population groups show the drug is “uniformly beneficial” in treating COVID-19


    Ivermectin real-time meta analysis


    Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations

    Published: 15 February 2017 – https://www.nature.com/articles/ja201711

    Satoshi Ōmura collecting soil from the very site where the fateful sample containing Streptomyces avermectinius (S. avermitilis) was taken in 1973. (Photo credit: Andy Crump).

    Ivermectin is continuing to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary.

    Ivermectin Key for Early COVID-19 Treatment: Dr. Paul Marik

    October 2022 – Zachary Stieber, Jan Jekielek – The Epoch Times

    Ivermectin, an anti-parasitic drug, has shown efficacy against COVID-19 in some studies as a prophylactic and treatment.

    “It’s antiviral, so it works against a whole host of RNA viruses. This is indisputable.

    It is anti-inflammatory. We know that there are multiple studies showing that ivermectin is a very powerful anti-inflammatory drug.

    We know that what it does is it stimulates a process called autophagy, which is very important in the process of healing. And it’s one of the main mechanisms that we use to help patients get rid of spike protein.

    And ivermectin, believe it or not, stimulates autophagy. The other thing it does, which is important, is it changes [and] improves the microbiome,”

    Anti-inflammatory activity of ivermectin in late-stage COVID-19

    DiNicolantonio JJ, Barroso-Aranda J, McCarty MF.
    Open Heart https://openheart.bmj.com/content/8/1/e001655

    A meta-analysis of 18 clinical studies to date examining the impact of ivermectin therapy in hospitalised COVID-19 patients has observed a roughly 68% reduction in mortality associated with its usage.

    Statement on the Irregular Actions of Public Health Agencies and Disinformation Campaign Against Ivermectin


    In February 2021, the British Ivermectin Recommendation Development (BIRD), an international meeting of physicians, researchers, specialists, and patients, followed a guideline development process consistent with the WHO standard. It reached a consensus recommendation that ivermectin, a verifiably safe and widely available oral medicine, be immediately deployed early and globally. The BIRD group’s recommendation rested in part on numerous, well-documented studies reporting that ivermectin use reduces the risk of contracting COVID-19 by over 90% and mortality by 68% to 91%.

    A similar conclusion has also been reached by an increasing number of expert groups from the United Kingdom (UK), ItalySpainUnited States (US), and a group from Japan headed by the Nobel Prize-winning discoverer of Ivermectin, Professor Satoshi Omura. Focused rebuttals that are backed by voluminous research and data have been shared with PHAs over the past months. These include the WHO and many individual members of its guideline development group (GDG), the FDA, and the NIH. However, these PHAs continue to ignore or disingenuously manipulate the data to reach unsupportable recommendations against ivermectin treatment. We are forced to publicly expose what we believe can only be described as a “disinformation” campaign astonishingly waged with full cooperation of those authorities whose mission is to maintain the integrity of scientific research and protect public health.

    The following accounting and analysis of the WHO ivermectin panel’s highly irregular and inexplicable analysis of the ivermectin evidence supports but one rational explanation: the GDG Panel had a predetermined, nonscientific objective, which is to recommend against ivermectin. This is despite the overwhelming evidence by respected experts calling for its immediate use to stem the pandemic. Additionally, there appears to be a wider effort to employ what are commonly described as “disinformation tactics” in an attempt to counter or suppress any criticism of the irregular activity of the WHO panel.

    The mechanisms of action of Ivermectin against SARS-CoV-2

    This evidence-based review article aims to discuss the mechanism of action of ivermectin against SARS-CoV-2 and summarizing the available literature over the years. A schematic of the key cellular and biomolecular interactions between Ivermectin, host cell, and SARS-CoV-2 in COVID-19 pathogenesis and prevention of complications have been proposed.

    The role of Ivermectin against the SARS-CoV-2 virus
    The targets of activity of Ivermectin can be divided into the following four groups:

    A. Direct action on SARS-CoV-2
    Level 1: Action on SARS-CoV-2 cell entry
    Level 2: Action on Importin (IMP) superfamily
    Level 3: Action as an Ionophore

    B. Action on host targets important for viral replication
    Level 4: Action as an antiviral
    Level 5: Action on viral replication and assembly
    Level 6: Action on post-translational processing of viral polyproteins
    Level 7: Action on Karyopherin (KPNA/KPNB) receptors

    C. Action on host targets important for inflammation
    Level 8: Action on Interferon (INF) levels
    Level 9: Action on Toll- like-Receptors (TLRs)
    Level 10: Action on Nuclear Factor-κB (NF-κB) pathway
    Level 11: Action on the JAK-STAT pathway, PAI-1 and COVID-19 sequalae
    Level 12: Action on P21 activated Kinase 1 (PAK-1)
    Level 13: Action on Interleukin-6 (IL-6) levels
    Level 14: Action on allosteric modulation of P2X4 receptor
    Level 15: Action on high mobility group box 1 (HMGB1),
    Level 16: Action as an immunomodulator on Lung tissue and olfaction
    Level 17: Action as an anti-inflammatory

    D. Action on other host targets
    Level 18: Action on Plasmin and Annexin A2
    Level 19: Action on CD147 on the RBC
    Level 20: Action on mitochondrial ATP under hypoxia on cardiac function


    A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

    Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

    Areas of uncertainty:
    We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

    Data sources:
    We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.

    The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit.

    Our certainty of evidence judgment was consolidated by the results of trial sequential analyses, which show that the required IS has probably already been met. Low-certainty evidence on improvement and deterioration also support a likely clinical benefit of ivermectin. Low-certainty evidence suggests a significant effect in prophylaxis.

    Overall, the evidence also suggests that early use of ivermectin may reduce morbidity and mortality from COVID-19. This is based on reductions in COVID-19 infections when ivermectin was used as prophylaxis, the more favorable effect estimates for mild to moderate disease compared with severe disease for death due to any cause, and on the evidence demonstrating reductions in deterioration.

    American Journal of Therapeutics: July/August 2021 – Volume 28 – Issue 4 – p e434-e460 doi: 10.1097/MJT.0000000000001402

    Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial

    Our study contributes evidence of the antiviral activity of ivermectin against SARS-CoV-2 in patients with COVID-19 through a randomized, controlled, outcome-assessor blinded clinical trial with innovative analyses that include the use of quantitative viral load determinations and measurement of ivermectin plasma levels, which allow an in-depth interpretation of the data and the identification of ivermectin systemic concentrations needed for a significant antiviral effect. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00239-X/fulltext

    Review the Efficacy of Ivermectin – Prophylaxis; Treatment of COVID-19

    American Journal of Therapeutics May 2021
    Kory, Pierre MD; Meduri, Gianfranco Umberto MD; Varon, Joseph MD; Iglesias, Jose DO; Marik, Paul E. MD

    Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.

    Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin.

    Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.


    Webinar Ivermectin against Covid-19
    Repurposing Ivermectin for COVID-19

    Concluding Remarks and Perspectives

    The available data from IVM clinical trials lack uniformity and have not established the optimal anti-viral dose. However, the evidence does support its safety and efficacy in improving survival rates, especially compared to the other aforementioned drugs. It is important to note that past research has demonstrated the importance of combined, rather than anti-viral monotherapy. Indeed, the use of a single drug does not efficiently suppress long-term replication of the virus (64). As evident by the ongoing clinical trials for the treatment of COVID-19, the most efficient decrease in mortality (0%) was largely a result of multiple prescribed drugs including IVM, hydroxychloroquine and azithromycin or IVM and doxycyline Table 1. Given the wide use of numerous drugs to treat COVID-19 patients, it remains imperative to explore the optimal combination of various therapies.


    Expert review report, Medical safety of Ivermectin

    Jacques Descotes MD, PharmD, PhD
    Professor Emeritus, Claude Bernard University of Lyon
    Fellow, US Academy of Toxicological Sciences
    Eurotox Registered Toxicologist

    March 2021 As per the request of MedinCell SA (France), I the undersigned certify to have perused the publicly available information relevant to conduct an extensive analysis of ivermectin safety in human beings. The aim of the present review is to propose an independent, evaluative judgement of this information which includes original scientific publications and literature reviews, case reports, and any other source provided it can be undisputedly tracked down and freely accessed.

    The author personally collected and reviewed all the cited information from the beginning of September 2020 to the end of February 2021.

    Dr. Satoshi Ōmura, co-developer of ivermectin: “A meta-analysis reported improvements of 83% in early treatment, 51% in late treatment, & 89% in the prevention of [COVID-19]. The probability of this judgment being a mistake is as low as 1 in 4 trillion.

    Morimasa Yagisawa, Ph.D.1,2, Patrick J. Foster, M.D.2,
    Hideaki Hanaki, Ph.D.1 and Satoshi Ōmura, Ph.D.1
    Kitasato University Ōmura Satoshi Memorial Institute
    Keio University Faculty of Pharmacy
    (Received for publication March 10, 2021)

    When the effectiveness of ivermectin for the COVID-19 pandemic is confirmed with the cooperation of researchers around the world and its clinical use is achieved on a global scale, it could prove to be of great benefit to humanity. It may even turn out to be comparable to the benefits achieved from the discovery of penicillin—said to be one of the greatest discoveries of the twentieth century. Here, one more use for ivermectin, which has been described as “miracle” or “wonder” drug, is being added. History has demonstrated that the existence of such natural product-derived compounds with such diverse effects is exceedingly rare.

    However, in order to pass on to posterity the fact that ivermectin has become widely used to control the world-shattering COVID-19 pandemic, only one simple action is required: the addition of only one word, “COVID-19”, to the 9th item (of the 11 listed) under the “Antiviral” category in the “Ivermectin: The Future” section of the Nobel Lecture’s record167) entitled “Splendid Gift from the Earth”.

    The BIRD Recommendation on the Use of Ivermectin for Covid-19

    Proceedings and conclusions of the British Ivermectin Recommendation Development meeting held on the 20th February 2021 in Bath, United Kingdom.

    This British Ivermectin Recommendation Development (BIRD) panel recommendation is the product of a collaborative philanthropic effort, involving an international group of health professionals, covid-19 patients and members of the public, for the greater good of humanity. The Evidence-based Medicine Consultancy Ltd, Bath, United Kingdom, which co-ordinated the effort, gratefully acknowledges the contributions that many individuals have made to this recommendation.

    This recommendation on ivermectin for covid-19 was developed using the standard procedures for guideline development as described in the World Health Organization Handbook for Guideline Development (2014). Briefly, these procedures include: (i) Identification of priority questions and outcomes; (ii) Evidence retrieval and synthesis; (iii) Assessment of the evidence; (iv) Formulation of the recommendation; and (v) Planning for implementation, dissemination, impact evaluation and updating. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for quantitative evidence was applied, to ensure the quality of the scientific evidence that forms the basis of the recommendation. An up-to-date systematic review and meta-analysis were conducted to prepare the evidence underpinning each of the priority questions.

    Study 107 pages online

    Swiss Policy Research

    Overview of all covid-19 ivermectin studies (IVMMETA)

    Ivermectin could cut Covid deaths by up to 75%, research suggests

    PUBLISHED: 00:57 GMT, 25 February 2021 | UPDATED: 01:23 GMT, 25 February 2021

    More than 30 trials across the world found that ivermectin causes ‘repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease.

    The peer-reviewed study, to be published in the US journal Frontiers of Pharmacology, says the evidence is so strong that the drug – used to treat head lice and scabies – should become a standard therapy everywhere, so hastening the global recovery.

    Study co-author Professor Paul Marik, director of emergency and pulmonary care at the Eastern Virginia Medical School in the US, said: ‘The data is overwhelming – we are in a pandemic, and this is an incredibly effective way to combat it. If we use ivermectin widely, our societies can open up.’

    Yesterday Dr Lawrie submitted a 97-page report to the World Health Organisation, urging it immediately to recommend ivermectin to treat Covid.

    It has been used by hundreds of millions of patients over the past 30 years, mainly in developing countries, and at around £50 per patient – less in some countries – is far cheaper than other new Covid treatments, such as the rheumatism drug tocilizumab, which costs £1,000 per patient.


    Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

    The antiviral effects of ivermectin on RNA viruses
    In a recent in vitro study, the Vero/hSLAM cells infected with the SARS-CoV-2 or COVID-19 virus were exposed to 5 µM ivermectin in 48 h, and a 5000-fold reduction in viral RNA compared with control was found [15]. The results showed that treatment with ivermectin effectively kills almost all viral particles within 48 h. The study was the first to assess the antiviral effect of ivermectin on COVID-19. The authors acknowledged that the drug may have antiviral effects by inhibiting the importin (IMP) α/β receptor, which is responsible for transmitting viral proteins into the host cell nucleus. The authors proposed human studies to confirm the potential benefits of ivermectin in the treatment of COVID-19. Although this study was the first to confirm the antiviral effect of ivermectin on COVID-19, other studies examined the antiviral effects of the drug on both RNA and DNA viruses, which are summarized in Table 1.

    In this systematic review, we showed antiviral effects of ivermectin on a broad range of RNA and DNA viruses by reviewing all related evidences since 1970. This study presents the possibility that ivermectin could be a useful antiviral agent in several viruses including those with positive-sense single-stranded RNA, in similar fashion.
    Since significant effectiveness of ivermectin is seen in the early stages of infection in experimental studies, it is proposed that ivermectin administration may be effective in the early stages or prevention. Of course, confirmation of this statement requires human studies and clinical trials. https://www.nature.com/articles/s41429-020-0336-z

    Ivermectin is effective for COVID-19: meta analysis of 24 studies


    • Ivermectin is effective for COVID-19. 100% of studies report positive effects. The probability that an ineffective treatment generated results as positive as the 24 studies to date is estimated to be 1 in 17 million (p = 0.00000006).
    • Early treatment is most successful, with an estimated reduction of 87% in the effect measured using a random effects meta-analysis, RR 0.13 [0.04-0.51].
    • 100% of the 10 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 74% in the effect measured using a random effects meta-analysis, RR 0.26 [0.12-0.56].

    Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?


    Background: Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa. Objective: To evaluate the impact of ivermectin interventions for onchocerciasis on the morbidity, mortality, recovery, and fatality rates caused by COVID-19. Method: A retrospective statistical analysis study of the impact of ivermectin against COVID-19 between the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the non-endemic 22 countries in Africa. The morbidity, mortality, recovery rate, and fatality rate caused by COVID-19 were calculated from the WHO situation report in Africa. We investigated the onchocerciasis endemic 31 countries and the non-endemic 22 countries. Statistical comparisons used by the Welch test of them in the two groups were made. Results: The morbidity and mortality were statistically significantly less in the 31 countries using CDTI. The recovery and fatality rates were not statistically significant difference. The average life expectancy was statistically significantly higher in the non-endemic countries. Conclusions: The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality. https://www.medrxiv.org/content/10.1101/2021.03.26.21254377v1

    Slovakia Becomes 1st EU Nation to Formally Approve Ivermectin

    The Slovakia Republic’s Minister of Health has formerly registered Ivermectin as an approved prophylaxis and treatment for SARS-CoV-2, the virus behind COVID-19. In breaking news, the authorization occurred yesterday as doctors received the news that they could proceed with formally authorized prescriptions both in hospitals and outpatient.

    On January 26, Health Minister Marek Krajci granted a permit for the unregistered drug as the drug has already been in use on a compassionate basis over the past half year. TrialSite interviewed Ondrej Halgas, a researcher from University of Toronto and originally from Slovakia.

    Halgas has been actively involved with a network organizing and lobbying for the drug’s approval during the pandemic. This landlocked Eastern European nation of 5.4 million people, a member of the European Union since 2004, just made history.

    A biochemist with the University of Toronto, Mr. Halgas, was just also showcased in a recent press release on this subject. 


    WHO-sponsored review of ivermectin RCT

    Dr Andrew Hill of the Department of Pharmacology at the University of Liverpool (UK) is currently performing a WHO-sponsored review and meta-analysis of randomized controlled trials of ivermectin against covid. In the following 12-minute video, Dr Hill is presenting his preliminary results, which indicate a highly significant 83% reduction in covid mortality (95% CI 65%-92%).


    youtube https://youtu.be/yOAh7GtvcOs
    Twitter blacklists European MEDICAL JOURNAL

    Twitter has blocked a link to an article in a peer-reviewed scientific journal that suggested the antiparasitic drug ivermectin could be useful against Covid-19. The platform claims the journal’s website is “potentially unsafe.”


    Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 – updated Dec 18, 2020

    Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin

    Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 – updated Dec 18, 2020

    Urgent appeal to the Government to investigate the effect of Ivermectin!

    Ivermectin and COVID-19.
    Recent research results show that Ivermectin has a strong preventive effect, accelerates recovery and increases the survival rate with COVID-19. Its use can relieve hospitals and save lives of patients. Therefore an urgent appeal to the Government to investigate the effect of Ivermectin!

    Website google translate Dutch to English – Ivermectine.nu

    Original Language Dutch https://www.ivermectine.nu

    Common asthma treatment reduces need for hospitalisation in COVID-19 patients

    Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.

    The STOIC study found that inhaled budesonide given to patients with COVID-19 within seven days of the onset of symptoms also reduced recovery time. Budesonide is a corticosteroid used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).

    Findings from the phase 2 randomised study, which was supported by the NIHR Oxford Biomedical Research Centre (BRC), were published on the medRxiv pre-print server.

    The findings from 146 people – of whom half took 800 micrograms of the medication twice a day and half were on usual care – suggests that inhaled budesonide reduced the relative risk of requiring urgent care or hospitalisation by 90% in the 28-day study period. Participants allocated the budesonide inhaler also had a quicker resolution of fever, symptoms and fewer persistent symptoms after 28 days.

    Professor Mona Bafadhel of the University’s Nuffield Department of Medicine, who led the trial, said: ‘There have been important breakthroughs in hospitalised COVID-19 patients, but equally important is treating early disease to prevent clinical deterioration and the need for urgent care and hospitalisation, especially to the billions of people worldwide who have limited access to hospital care.


    Dr. Scott Atlas Hydroxychloroquine very safe

    Scott W. Atlas is an American neuroradiologist, professor, commentator, and health care policy advisor. He is the Robert Wesson Senior Fellow at the Hoover Institution. In August 2020, Atlas was selected by President Donald Trump to serve as an advisor on the COVID-19 pandemic.

    The drug hydroxychloroquine has gotten a bad rap thanks to a politics, media hype, and some “garbage” medical research, according to Dr. Scott Atlas, a member of the White House coronavirus task force.

    “Hydroxychloroquine is super safe. It’s a complete myth, it’s a total distortion, to say that, oh, my God, this drug is very dangerous for people,” said Dr. Atlas. “It’s been used for 65 or 70 years, not just prophylactically for malaria, which I used it myself for that many years ago, but also used for people with things like rheumatic arthritis, auto-immune-type diseases. Very safe drug.”

    https://amp.washingtontimes.com/news/2020/aug/29/hydroxychloroquine-uproar-shows-objective-science-/ Reader view backup for download:

    Hydroxychloroquine studies

    COVID-19 early treatment: real-time analysis 
    Open link for latest data: https://c19early.com/https://hcqmeta.com/

    Global HCQ studies. PrEP, PEP, and early treatment studies show efficacy

    October 8, 2004 Chloroquine may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

    We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC50 of chloroquine for antiviral activity (8.8 ± 1.2 μM) was significantly lower than its cytostatic activity; CC50 (261.3 ± 14.5 μM), yielding a selectivity index of 30. The IC50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.


    COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study

    December 2020
    First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

    Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

    Significantly reduced hospitalisation rates in the treatment group.

    Reduced mortality rates in the treatment group.


    Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients

    December 2020 – Following a global push for the use of hydroxychloroquine and chloroquine, there is ongoing discussion about the effectivity of these drugs.

    The findings of this observational study provide crucial data on a potential protective effect of hydroxychloroquine in non-ICU, hospitalized, COVID-19 patients.

    Early treatment with HCQ on the first day of admission is associated with a 53% reduction in risk of transfer to the ICU for mechanical ventilation.

    This protective effect was not observed for chloroquine; therefore, these drugs cannot be regarded as interchangeable.

    The analysis included 1064 patients from 14 hospitals: 566 patients received treatment with either HCQ (n = 189) or CQ (n = 377), and 498 patients received no treatment. In a multivariate propensity-matched weighted competing regression analysis, there was no significant effect of (H)CQ on mortality on the COVID ward. However, HCQ was associated with a significantly decreased risk of transfer to the ICU (hazard ratio (HR) = 0.47, 95% CI = 0.27–0.82, p =  0.008) when compared with controls. This effect was not found in the CQ group (HR = 0.80, 95% CI = 0.55–1.15, p =  0.207), and remained significant after competing risk analysis.

    The results of this observational study demonstrate a lack of effect of (H)CQ on non-ICU mortality. However, we show that the use of HCQ — but not CQ — is associated with a 53% reduction in risk of transfer of COVID-19 patients from the regular ward to the ICU. Recent prospective studies have reported on 28-day, all-cause mortality only; therefore, additional prospective data on the early effects of HCQ in preventing transfer to the ICU are still needed.

    Hydroxychloroquine study finds 84% fewer hospitalizations

     November24, 2020

    ‘What differentiates this study is that patients were diagnosed very early with COVID-19 in an outpatient setting, and only high-risk patients were treated early on’

    A peer-reviewed study analyzing the effectiveness of a triple drug cocktail including hydroxychloroquine in treating COVID-19 patients found that the treatment was effective and that it significantly reduced hospitalization and mortality rates for those in the treatment group.


    HCQ is effective for COVID-19 when used early: analysis of 115 studies

    HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 115 studies to date is estimated to be 1 in 20 million (p = 0.000000049).

    Early treatment is most successful, with 100% of studies reporting a positive effect and an estimated reduction of 63% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.37 [0.30-0.47].

    100% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.002.

    There is evidence of bias towards publishing negative results. Significantly more retrospective studies report negative results compared to prospective studies, p = 0.05.

    Significantly more studies in North America report negative results compared to the rest of the world, p = 0.005. Full article online https://hcqmeta.com

    Global HCQ studies show high effectiveness

    Global HCQ studies. PrEP, PEP, and early treatment studies show high effectiveness, while late treatment shows mixed results https://c19study.com

    The latest international testing of hydroxychloroquine treatment of coronavirus shows countries that had early use of the drug had a 79% lower mortality rate than countries that banned the use of the safe malaria drug. 

    65 scientific studies have shown hydroxychloroquine is effective when used early against COVID19

    Above account is suspended by twitter; saved content below.

    2005 – Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

    Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.

    We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.

    Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.

    Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/

    HCQ fabricated / bogus study used by the WHO

    This is probably the biggest scandal of all. A complete bogus study used by the WHO to stop using HCQ 

    HCQ need to be available immediately for physicians to prescribe

    Hydroxychloroquine studies conducted by Oxford and the WHO produced an astounding mortality rate 34 times that of other recent studies. As a result the FDA revoked emergency use of the drug in the U.S. Now, data shows potentially lethal doses of HCQ were used on trial participants. Dr. Jim Meehan details this developing scandal. 

    This video was removed from Youtube July 30th, 2020

    How a false hydroxychloroquine narrative was created, and more

    Meryl Nass, M.D.
    It is remarkable that a large series of events taking place over the past 3 months produced a unified message about hydroxychloroquine, and produced similar policies about the drug in the US, Canada, Australia, NZ and western Europe.  The message is that generic, inexpensive hydroxychloroquine is dangerous and should not be used to treat a potentially fatal disease, Covid-19, for which there are no (other) reliable treatments. 

    Hydroxychloroquine has been used safely for 65 years in many millions of patients.  And so the message was crafted that the drug is safe for its other uses, but dangerous when used for Covid-19.  It doesn’t make sense, but it seems to have worked.

    Full article: https://anthraxvaccine.blogspot.com/2020/06/how-false-hydroxychloroquine-narrative.html


    Hydroxychloroquine became 2020’s Dirty Word

    By Sara Carter Aug. 22, 2020

    What is the American public to believe about getting the best treatment possible for COVID-19? In fact, most Americans don’t know what to believe and it’s with good reason. 

    Everyone assumes that their doctors, or emergency room physician are giving the best advice based on the information available during our most difficult times. Unfortunately, that is not always the case. Why? Because many of our doctors and hospitals lack the necessary studies that would give them the answers they need regarding the virus from China that has turned the world upside down. … Full article link

    Hydroxychloroquine Azithromycin Zinc has been widely misrepresented

    American Journal of Epidemiology May 27. Azithromycin Hydroxychloroquine Zinc “These medications need to be widely available and promoted immediately for physicians to prescribe” 

    “Hydroxychloroquine + azithromycin has been widely misrepresented in both clinical reports and public media..” 

    “Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy” 

    Interview Doctor – fabricated HCQ study published …

    … makes it really hard to have respect for major journals when they publish studies that are really fabricated.

    1 min 16: … in essence HCQ works like a vaccine, in some sense, it’s prophylactic and yes that makes the need for a vaccine is a lot less.

    It’s really hard to have respect for major journals when they publish studies that are really fabricated

    HCQ Death by overdose

    Oxford is the circus of a significant scam around the Recovery clinical trial for Covid-19 therapies.  Significant errors, excessive doses of hydroxychloroquine on very sick patients with many comorbidities, resulting in what may appear as “death by overdose”, could easily have masked a beneficial effect of the molecule.

    HCQ Politicians lied and patients died

    Hydroxy track record: Politicians lied and patients died

    When a WorldTribune contributing editor approached a primary care physician in the Raleigh, NC area for a prescription to hydroxychloroquine last week, he was told, “I would not be comfortable going that route. I have been getting letters from the state medical board.” The governor of North Caroline, Roy Cooper, is a Democrat.

    Hydroxychloroquine works episode II “Stupefying effects in 53 countries”

    “It is impressive to see such consequences in so many countries in the world, and that a fraudulent publication can have such an impact on public health. This analysis should attract the attention of competent epidemiologists ” Professor Christian Perronne


    COVID Analysis twitter feed

    Dr. Zev Zelenko Twitter feed

    COVID19 is a Pandemic of fear, fleeing in logic in which we restrict reality, resulting in destroying society and at the same time creating dangerous social mechanisms.